65386-28-9

Usage

Chemical Properties

Colourless Thick Oil

Uses

4-(ChloroMethyl)-2-isopropylthiazole hydrochloride is a useful synthetic intermediate.

InChI:InChI=1/C7H10ClNS.ClH/c1-5(2)7-9-6(3-8)4-10-7;/h4-5H,3H2,1-2H3;1H

Upstream product

• 13515-65-6 thioisobutyramide 
• 534-07-6 1,3-Dichloroacetone 

Relevant academic research and scientific papers

Preparation method for 2-isopropyl-4-(methyl aminomethyl) thiazole hydrochloride

The invention belongs to the field of medical intermediate synthesis, relates to a preparation method for ritonavir intermediate synthesis and particularly relates to a preparation method for 2-isopropyl-4-(methyl aminomethyl) thiazole hydrochloride. Isobutyric acid firstly reacts with thionyl chloride, and then ammonium sulfide and ammonium hydroxide are subjected to sulfo-reaction and aminating reaction, the existing process of using phosphorus pentasulfide for performing sulfo-reaction after acylation is replaced, the heavy smell is prevented from generating in the preparation process to avoid the environmental pollution. According to the invention, 1,3-dihydroxy acetone is adopted for replacing 1,3-dichloroacetone with high price, heavy smell and high pollution, the cost is saved and the preparation is environmentally friendly. According to the preparation method provided by the invention, the process is simple, the yield higher than that of the prior art and the preparation method is suitable for industrial production.

SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS

Compounds of Formula I: and pharmaceutically acceptable salts thereof in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal

ACID ADDITION SALT OF 2-ISOPROPYL-4-(((N-METHYL)AMINO)METHYL)THIAZOLE AND ITS?USE IN THE PREPARATION OF RITONAVIR

The present invention relates to a novel acid addition salt of 2-Isopropyl-4-(((N-methyl)amino)methyl)thiazole of Formula (I) which is a useful intermediate for preparing HIV protease inhibitors. The present invention further provides a process for preparing ritonavir, a HIV protease inhibitor, using the compound of Formula (I).

Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy

The structure-activity studies leading to the potent and clinically efficacious HIV protease inhibitor ritonavir are described. Beginning with the moderately potent and orally bioavailable inhibitor A-80987, systematic investigation of peripheral (P3 and P2') heterocyclic groups designed to decrease the rate of hepatic metabolism provided analogues with improved pharmacokinetic properties after oral dosing in rats. Replacement of pyridyl groups with thiazoles provided increased chemical stability toward oxidation while maintaining sufficient aqueous solubility for oral absorption. Optimization of hydrophobic interactions with the HIV protease active site produced ritonavir, with excellent in vitro potency (EC50 = 0.02 μM) and high and sustained plasma concentrations after oral administration in four species. Details of the discovery and preclinical development of ritonavir are described.

Pharmaceutical composition

A solid pharmaceutical composition is disclosed which comprises a pharmaceutically acceptable adsorbent or a mixture of pharmaceutically acceptable adsorbents to which is adsorbed a mixture of (1) a pharmaceutically acceptable organic solvent or a mixture of pharmaceutically acceptable organic solvents, (2) an HIV protease inhibiting compound and (3) one or more pharmaceutically acceptable acids. The solid composition can optionally be encapsulated in a hard gelatin capsule.

Pharmaceutical composition for inhibiting HIV protease

A pharmaceutical composition is disclosed which comprises a solution of an HIV protease inhibiting compound in a pharmaceutically acceptable organic solvent comprising a mixture of (1) (a) a solvent selected from propylene glycol and polyethylene glycol or (b) a solvent selected from polyoxyethyleneglycerol triricinoleate, polyethylene glycol 40 hydrogenated castor oil, fractionated coconut oil, polyoxyethylene (20) sorbitan monooleate and 2-(2-ethoxyethoxy)ethanol or (c) a mixture thereof and (2) ethanol or propylene glycol.

RETROVIRAL PROTEASE INHIBITING PIPERAZINE COMPOUNDS

Retroviral protease inhibiting compounds of the formula: STR1 are disclosed.

RETROVIRAL PROTEASE INHIBITING COMPOUNDS

A retroviral protease inhibiting compound of the formula: STR1 is disclosed wherein R 1, R 2, R 5, R 6, Y m and Y' n are herein defined.

Phenylpiperazine derivatives

Phenylpiperazine derivatives of formula (I): STR1 where R1 is benzyl, C1-6 alkyl or optionally substituted phenyl; R2 is optionally substituted phenyl; R3 is hydrogen or C1-4 alkyl; Q is furan, thioph